Abstract:Background. Plasma S100A1 protein is a novel inflammatory biomarker associated with acute myocardial infarction and neurodegenerative disease's pathophysiological mechanisms. This study aimed to determine the levels of this protein in patients with acute ischemic stroke early in the disease progression and to investigate its role in the pathogenesis of acute ischemic stroke.Methods. A total of 192 participants from hospital stroke centers were collected for the study. Clinically pertinent data were recorded. The volume of the cerebral infarction was calculated according to the Pullicino formula. Multivariate logistic regression analysis was used to select independent influences. ROC curve was used to analyze the diagnostic value of AIS and TIA. The correlation between S100A1, NF -KB p65, and IL-6 levels and cerebral infarction volume was detected by Pearson correlation analysis.Results. There were statistically significant differences in S100A1, NF -KB p65, and IL-6 among the AIS,TIA, and PE groups (S100A1, [230.96 +/- 39.37] vs [185.85 +/- 43.24] vs [181.47 +/- 27.39], P < 0.001; NF -KB p65, [3.99 +/- 0.65] vs [3.58 +/- 0.74] vs [3.51 +/- 0.99], P = 0.001; IL-6, [13.32 +/- 1.57] vs [11.61 +/- 1.67] vs [11.42 +/- 2.34], P < 0.001). Multivariate logistic regression analysis showed that S100A1 might be an independent predictive factor for the diagnosis of disease (P < 0.001). The AUC of S100A1 for diagnosis of AIS was 0.818 (P < 0.001, 95% CI [0.749-0.887], cut off 181.03, J max 0.578, Se 95.0%, Sp 62.7%). The AUC of S100A1 for diagnosis of TIA was 0.720 (P = 0.001, 95% CI [0.592-0.848], cut off 150.14, J max 0.442, Se 50.0%, Sp 94.2%). There were statistically significant differences in S100A1, NF -KB p65, and IL-6 among the SCI,MCI, and LCI groups (S100A1, [223.98 +/- 40.21] vs [225.42 +/- 30.92] vs [254.25 +/- 37.07], P = 0.001; NF -KB p65, [3.88 +/- 0.66] vs [3.85 +/- 0.64] vs [4.41 +/- 0.45], P < 0.001; IL-6, [13.27 +/- 1.65] vs [12.77 +/- 1.31] vs [14.00 +/- 1.40], P = 0.007). Plasma S100A1, NF -KB p65, and IL-6 were significantly different from cerebral infarction volume (S100A1, r = 0.259, P = 0.002; NF -KB p65, r = 0.316, P < 0.001; IL-6, r = 0.177, P = 0.036). There was a positive correlation between plasma S100A1 and IL-6 with statistical significance (R = 0.353, P < 0.001). There was no significant positive correlation between plasma S100A1 and NF -KB p65 (R < 0.3), but there was statistical significance (R = 0.290, P < 0.001). There was a positive correlation between IL-6 and NF -KB p65 with statistical significance (R = 0.313, P < 0.001).Conclusion. S100A1 might have a better diagnostic efficacy for AIS and TIA. S100A1 was associated with infarct volume in AIS, and its level reflected the severity of acute cerebral infarction to a certain extent. There was a correlation between S100A1 and IL-6 and NF -KB p65, and it was reasonable to speculate that this protein might mediate the inflammatory response through the NF -KB pathway during the pathophysiology of AIS.

To study the correlation of serum S-100 protein level with the severity of stroke and its prognostic implication

High S100B Levels in Cerebrospinal Fluid and Peripheral Blood of Patients with Acute Basal Ganglial Hemorrhage Are Associated with Poor Outcome.

Predicting Short- and Long-Term Functional Outcomes Based on Serum S100B Protein Levels in Patients with Ischemic Stroke

Diagnostic value and mechanism of plasma S100A1 protein in acute ischemic stroke: a prospective and observational study

Serum S-100B adds incremental value for the prediction of symptomatic intracranial hemorrhage and brain edema after acute ischemic stroke

The association between serum S100β levels and prognosis in acute stroke patients after intravenous thrombolysis: a multicenter prospective cohort study

The Prognostic Value of Serum Pregnancy-Associated Plasma Protein A, S100 and High Sensitivity C-reactive Protein in Acute Ischemic Stroke Patients Without Heparin Administration.

Role of S100B Serum Concentration as a Surrogate Outcome Parameter After Mechanical Thrombectomy

NERVE GROWTH FACTOR AND S100B IN BLOOD AND CEREBROSPINAL FLUID AS INDICATORS OF THE SEVERITY OF ISCHEMIC STROKE

Brain derived proteins as markers of acute stroke: Their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring

S100B and Ischemic Stroke

Study of the Change of Serum S100β Protein and CRP Content in Patients with Acute Cerebral Infarction

Effects of subcutaneous low molecular weight heparin and intravenous unfractionated heparin on serum S100 concentrations in patients with cerebrovascular diseases.

Correlation of the Serum Albumin Levels in Ischemic Stroke with the Prognosis of Its TOAST Subtypes

Clinical Evaluation of Prognosis of Severe Posttraumatic Brain Injuries by Using S-100B

Relationship Between Poststroke Serum WBC Level and the Severity and Prognosis of Ischemic Stroke

Utility of serum amyloid A as a potential prognostic biomarker of acute primary basal ganglia hemorrhage

The correlation study between the level of high-sensitivity C-reactive protein in acute phase of ischemic ;stroke and progressive stroke

Prognostic Utility of Serum Biomarkers in Intracerebral Hemorrhage: A Systematic Review

Plasma S100A8/A9 Concentrations and Clinical Outcomes of Ischemic Stroke in 2 Independent Multicenter Cohorts.

Current Trends in Stroke Biomarkers: The Prognostic Role of S100B and GFAP